Video
Dr. Yilmaz on the Benefit of Quizartinib Triplet in AML
Author(s):
Musa Yilmaz, MD, discusses composite complete remission and bone marrow transplant rates observed in a phase 1/2 trial in patients with FLT3-ITD–mutated acute myeloid leukemia.
Musa Yilmaz, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses composite complete remission (CRc) and bone marrow transplant rates observed in a phase 1/2 trial (NCT03661307) in patients with FLT3-ITD–mutated acute myeloid leukemia (AML).
This trial evaluated the efficacy and safety of decitabine plus quizartinib and venetoclax (Venclexta) in patients with newly diagnosed or relapsed/refractory FLT3-ITD–mutated AML who are ineligible for intensive induction chemotherapy.
The CRc rate in patients with relapsed/refractory disease was 82%, Yilmaz says. Additionally, bone marrow biopsies conducted by day 14 of the regimen revealed that 46% of these patients had bone marrow blasts of 5% or less, displaying an encouraging response rate in the relapsed/refractory cohort, Yilmaz notes.
Regarding safety, the 30-day mortality rate in this cohort was 0%, showing this regimen to be tolerable, with no induction mortality, Yilmaz says. A total of 43% of these patients proceeded to allogeneic bone marrow transplant, which are promising results, as transplant is the only practical way to treat this disease, Yilmaz concludes.
